Background Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressurelowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans.
Background Three peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126-amino acid atrial natriuretic factor prohormone (proANF), which have blood pressurelowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans.
Methods and Results Thirty-six healthy, normotensive human volunteers (18 men and 18 women, ages 20 to 58 years) were divided into six similar groups based on age, sex, weight, blood pressure, and heart rate. After a 60-minute baseline period, 100 ng of proANFs 1-30, 31-67, 79-98, or ANF/kg body wt per minute was given intravenously for 60 minutes followed by a 3-hour postinfusion data collection period. Each of the atrial natriuretic peptides decreased systolic and diastolic blood pressures (P<.05), with proANF 31-67 causing the largest decrease. Urine flow increased 4to 12-fold and was still significantly increased (P<.01) for 2 to 3 hours after stopping the respective infusions of proANFs 1-30, 31-67, and 79-98. Atrial natriuretic factor (ANF) increased urine flow 4to 11-fold but by 2 hours after infusion was significantly increased in only 1 of 6 subjects. Sodium excretion increased 3-to 8-fold, 3to 6-fold, 0to 2-fold (NS), and 3-to 11-fold, respectively, with proANFs 1-30, 31-67, 79-98, and ANF. Natriuretic effects of proANFs 1-30 and 31-67 were significantly prolonged (P<.001) compared with ANF. ProANFs 1-30, 31-67, 79-98, and ANF increased potassium excretion 2to 3-fold, 0-fold, 3to 4-fold, and 2-fold, respectively. Highperformance gel permeation chromatography followed by the respective radioimmunoassays revealed that proANFs 1-30, 31-67, 79-98, and 68-98, as well as ANF circulate as distinct peptides.
Conclusions ProANFs 1-30, 31-67, and 79-98, as well as ANF have significant blood pressure-lowering and diuretic properties. ProANFs 1-30 and 31-67 also have natriuretic properties in humans that are significantly (P<.001) prolonged compared with ANF. ProANF 79-98, although not possessing any natriuretic property, is the strongest stimulator of potassium excretion of the four atrial natriuretic peptides. (Circulation. 1994; 90:1129 -1140 Key Words * peptides * vasodilation * sodiumpotassium A trial natriuretic factor (ANF), the 28-amino acid carboxy terminal end of the 126-amino acid ANF prohormone (proANF), has natriuretic, diuretic, and potent vasodilator properties.1-3 We have found that peptides from the 98-amino acid N-terminus of this prohormone consisting of amino acids 1-30 (proANF 1-30, long-acting sodium stimulator), (proANF 31-67, vessel dilator), and 79-98 (proANF 79-98, kaliuretic stimulator) also have vasodilatory,4,5 natriuretic,5 and diuretic5 properties nearly equal to ANF in animal experiments. The mechanism of action of the N-terminal ANF prohormone peptides is similar to ANF with proANFs 1-30, 31-67, and 79-98, each activating particulate guanylate cyclase (E.C. 4.6.1.2) with a resultant increase in the intracellular messenger cyclic GMP.4,6 Which of the atrial peptides will activate guanylate cyclase is determined by their specific receptors, with proANFs 1-30 and 31-67 having distinct and separate receptors from the ANF receptors.78 ProANF 31-67 has another action in the inner medullary collecting duct, where it inhibits sodium reabsorption by inhibiting the Na+-K+ ATPase, which ANF does not inhibit. 9 The mechanism of action of proANF 31-67 in the intermedullary collecting duct involves the generation of prostaglandin E2, which appears to be the mediator of the Na+-K+ ATPase inhibition by proANF ing.18 These peptides are also released simultaneously in vitro in isolated perfused rat atria by atrial distension. '9 The present study was designed to determine whether peptides derived from the NH2-terminal portion of the ANF prohormone have diuretic, natriuretic, kaliuretic, and/or blood pressure-lowering effects in humans. ProANFs 1-30, 31-67, and 79-98 were tested and compared with ANF in their ability to lower systolic and diastolic blood pressures and to increase urine volume, urine sodium excretion, and urine potassium excretion.
Methods

Healthy Volunteers
Thirty-six healthy subjects (18 men and 18 women; age, 20 to 58 years; average, 32 years; all normotensive with blood pressures <125/80 mm Hg) were studied. These subjects had heart rates ranging from 56 to 80 beats per minute, with respiration rates between 12 and 14 per minute. These volunteers were divided into six similar groups, with age, sex, weight, blood pressure, and heart rate of each shown in Table 1 . None of the volunteers had any known disease. Of importance, none of the subjects had any abnormality of sodium or water metabolism. None of the volunteers were taking any medication. Informed consent was obtained from each of the volunteers after the nature and possible consequences of the studies were fully explained. This study was approved by the Institutional Review Board of the University of South Florida Health Sciences Center and the Research Committee of the James A. Haley Veterans Hospital. This study was also approved by the United States Food and Drug Administration (FDA IND No. 32,119).
Experimental Protocol
The experimental protocol is outlined in Fig 1. After obtaining written informed consent, an Insyte-w, 20-gauge, 12-in catheter was placed into the forearm of each subject for infusion and blood sampling. A 60-minute baseline period preceded any infusion. A total volume of 20 mL of normal saline (0.9% sodium chloride, with or without peptides) was infused by a constant-rate infusion pump over a 60-minute time period. Blood and urine samples were obtained every 20 minutes during the infusion and at 30-minute time intervals during the 1-hour baseline and 3-hour postinfusion time periods. One hundred nanograms per kilogram of body weight per minute was chosen for the infusion dosage of these atrial natriuretic peptides because the rate of release of the N-terminal ANF prohormone peptides from the atrium of the heart with physiological stimuli is 138-292 ng/kg body wt per minute, whereas the release rate of ANF from the atrium is 76 ng/kg bodywt per minute.20 Molar equivalents of 100 ng/kg body wt dose are 32, 29, 26, and 46 pmol/kg body wt for ANF, proANFs 1-30, 31-67, and 79-98, respectively. Thus, the concentrations used in this investigation are in the physiological range based on the release rates for the N-terminal ANF prohormone peptides and slightly above the physiological range for ANF.
Each of the subjects ingested their usual diet until the evening before the study. All subjects were studied in the morning after an overnight fast, beginning their baseline period at 8:00 AM.
Each volunteer was studied in the seated position. After completion of the 60-minute baseline period, to maintain a similar plasma volume throughout the study, orange juice (Na+=0.001 mmol/L; K+=0.046 mmol/L) was given orally in milliliters for each mol/L of urine output at the above time periods. Each volunteer received only one peptide infusion.
Purity of the Atrial Natriuretic Peptides
The human forms of proANFs 1-30, 31-67, 79-98, and ANF (ie, proANF 99-126) were synthesized by Penninsula Labora-tories, Inc. Before their use in these studies, samples of these commercially synthesized peptides were subjected to highpressure liquid chromatography (HPLC) to determine purity using a Novapak C18 (5 ,um) cartridge column. The flow rate for the HPLC study was 1 mL/min with 0.1% trifluoroacetate (TFA) solvent in pump A and 60% acetonitrile in 0.1% TFA in pump B, with a gradient of 0% to 60% acetonitrile achieved in 40 minutes. This evaluation verified purity and authenticity when compared with the known HPLC elution profile"5 of these peptides. After determining that the respective peptides were pure, the peptides were dissolved in 0.9% saline solution in the hospital pharmacy, where pyrogen and sterility testing was performed before dispensing the 100 ng/kg body wt concentrations of each peptide into two 10-mL syringes. Each 10-mL syringe was infused over a 30-minute time period. After completing the experiment, each of the syringes and the infusion catheter were examined by radioimmunoassays described below to determine the amount of the respective peptides that may have remained within the syringes or tubing. Approximately 5% of each peptide remained on the walls of the syringes and tubing after completion of the infusion.
Measurement of Atrial Natriuretic Peptides
Each of the blood samples and flushings of the syringes and tubing with 4 mL of 0.9% sodium chloride were collected into chilled 5-mL ethylenediaminetetraacetic acid (EDTA) tubes to prevent proteolytic breakdown of any peptides that might be present. These samples were transported on ice and immediately centrifuged at 3000g for 15 minutes. After centrifugation, each sample was extracted with 100% ethanol (1:2 dilution), vortexed, and allowed to stand at 4°C for 30 minutes.15 Radioimmunoassays to measure peptides from the N-terminus of the ANF prohormone were devised to amino acids 1-30, 31-67, and 79-98 of the 126-amino acid prohormone; the C-terminal ANF prohormone assay measures amino acid 99-126 of the prohormone, ie, ANF, as described previously by our laboratory.'5-'7 For each radioimmunoassay, the extracted plasma was first reconstituted in 100 ,L 0.1 mol/L phosphate buffer (pH 7.4) containing 0.05 mol/L NaCl, 0.1% bovine serum albumin, 0.1% Triton X-100, and 0.01% NaN3. To the redissolved sample, 100 ,uL (0.03 mg) of rabbit IgG plus 100 ,gL of the respective antisera were added and incubated for 24 hours. Then, 100 gL "25I-labeled peptides (10000 cpm) was added, mixed, and incubated for 18 hours at 4°C. The precipitation of the antibody-bound tracer was accomplished by adding 100 ,uL of goat anti-rabbit globulin after the above 18-hour period and incubating this mixture for 2 hours at room temperature. Each tube was then centrifuged at 3000g for 20 minutes. The supernatant was aspirated and the pellet counted in a gamma counter. All determinations were performed in triplicate. The interassay coefficient of variation for proANFs 1-30, 31-67, 79-98, and ANF radioimmunoassays were 4.8%, 5.3%, 5.5%, and 5.7%, respectively. The interassay coefficient of variation was 8% for proANFs 1-30 and 31-67; proANF 79-98 and ANF intra-assay variations were 7.6% and 6.9%.
Recovery was examined by adding synthetic unlabeled proANFs 1-30, 31-67, and 79-98 and ANF at 100, 200, and 400 pg/mL to pooled plasma. Recovery for proANF 1-30 was 83.5±13.2%; proANF 31-67 recovery was 100.9+8.9%. Recovery of proANF 79-98 was 86.8+9.6%; ANF was 92+11%.
The respective IC5,s were 180, 120, 47, and 11 fmol/tube; the lowest detectable concentrations were 40, 35, 5, and 1.4 fmol/tube for proANFs 1-30, 31-67, 79-98, and ANF radioimmunoassays (RIAs), respectively. Serial dilution of pooled plasma has revealed excellent parallelism of standards and unknowns in these assays.15-"7 High-Performance Gel Permeation Chromatography
The molecular forms of the immunoreactive proANF peptides and ANF in plasma were determined by high-perfor- 109±4/75±2 70±4 ProANF indicates atrial natriuretic factor prohormone; ANF, atrial natriuretic factor; and bpm, beats per minute. There are two sets of controls for these investigations. The first set received neither saline nor peptide to determine actual basal sodium, potassium, and urine excretion throughout the 5-hour investigative period, whereas the saline controls received a total of 20 mL of 0.9% saline infused over 1 hour as a control for the sodium content and volume of the peptide infusions. The respective peptides were dissolved in 20 mL of 0.9% saline, which was infused over 60 minutes.
There was no significant difference in the age, sex, weight, heart rate, or blood pressure of the individuals in the six groups when evaluated by one-way ANOVA. mance gel permeation chromatography (HP-GPC). Fifty milliliters of plasma pooled from 5 normal subjects was extracted with 100 mL of 100% ethanol (1:2 dilution) and then dried with low-flow nitrogen. This plasma extract was then resuspended in 100 ,uL of HP-GPC column mobile phase (10 mmol/L trifluoroacetic acid containing 0.3 mol/L sodium chloride and 30% acetonitrile) for HP-GPC assay as described previously.16,21 These 100-yL samples were applied to a TSK-GEL G2000SW column (7.5 x600 mm equipped with a guard column, 7.5 x75 mm; Toyo Soda) and eluted isocratically with HP-GPC column mobile phase at a flow rate of 0.3 mL/min. Fractions (0.3 mL) were collected, dried, then assayed for proANFs 1-30, 31-67, 79-98, and ANF by their respective RIAs described above. Blue dextran (2000000 MW) and p-aminohippuric acid (216 MW) were used to determine the void and total volumes of the column. To calibrate the column, carbonic anhydrase (29 000 MW), myoglobin' (16 900 MW), cytochrome C (12 384 MW), vasoactive intestinal peptide (3300 MW), and (tryl)-somatostatin (1730 MW) were used. The elution positions of proANFs 1-30, 31-67, 79-98, and ANF were determined using 'MI-labeled and unlabeled synthetic human forms of these peptides. Recoveries of these labeled peptides were as follows: 77% for ANF, 74% for proANF 1-30, 76% for proANF 79-98, and 82% for proANF 31-67. HP-GPC was repeated three times for each of the RIAs.
Measurement of Sodium, Potassium, and Osmolality
Sodium and potassium concentrations in the study were measured by flame photometry (Instrumentation Laboratory 943). Osmolality was measured by a microosmeter (Precision Systems, Inc).
Statistical Analysis
The data obtained in this investigation are illustrated as mean+SEM. Differences in measurements between subjects or groups of subjects were evaluated by the one-way ANOVA. Measurements obtained in the same subject over time were evaluated by the repeated measures of ANOVA. Maximum changes in systolic and diastolic blood pressures within groups were determined by a paired Student's t test. To be considered statistically significant, we required a probability value to be <.05 (95% confidence limits). Each of these peptides decreased systolic blood pressure more than diastolic blood pressure (Fig 2) . In one subject (No. 2 of ANF group of Table 1 ), blood pressure decreased 50 mm Hg systolic and 20 mm Hg diastolic abruptly 40 minutes after the ANF infusion began. She became lightheaded and pale in complexion. Placing this subject in the supine position increased her systolic blood pressure 30 mm Hg within 1 minute, with her lightheadedness ceasing, but her diastolic blood pressure required When this one subject whose blood pressure response differed markedly from the other members of the ANF group is deleted, the group with the largest decrease in blood pressure (10/6.3 mm Hg) was the proANF 31-67 group. This decrease in blood pressure secondary to proANF 31-67, however, was not significantly greater than ANF or the other N-terminal ANF prohormone-derived peptides. The control groups with and without saline had no decrease in either systolic or diastolic blood pressure; rather, in both groups their blood pressure increased slightly during their 4-hour combined infusion and postinfusion periods ( Fig 2) . In this and the results that follow, it should be pointed out that each individual also serves as his or her own control. The 60-minute time period referred to in tables and figures (which is the time period immediately before beginning one of the respective infusions) serves as the control (baseline) value in the individual subjects with which one can compare any effects observed at later time points in this investigation. The blood pressure decreases referred to above and the results of enhancing sodium excretion and so forth are the amount of decrease in blood pressure (or increase in sodium excretion and so forth) compared with the respective preinfusion measurement (ie, that is, 60-minute time period) in each of the subjects. The two control groups consisting of healthy individuals who received 20 mL of 0.9% saline (vehicle) and those individuals who received no volume load have been added to demonstrate that blood pressure, sodium excretion, and so forth do not change by chance alone during the time period used in this investigation. Urine volume did not increase significantly in the control subjects during the combined 5-hour baseline and experimental periods (Fig 3) . Urine volume did increase significantly (P<.01) secondary to proANFs 1-30, 31-67, 79-98, and ANF (Fig 3) . Basal urine output and the increase in urine flow varied markedly among the individ- ual subjects. The data on urine flow in individual subjects are therefore detailed in Table 2 . In the majority of individuals, urine flow was still significantly (P<.05) increased 3 hours after stopping the infusions of proANFs 1-30, 31-67, and 79-98. With ANF, however, only one individual had a significantly increased urine flow 3 hours after infusion ( Table 2 ). Urine flow secondary to ANF was of shorter duration, with 3 individuals having increased urine flow 1 to 2 hours after infusion. In 2 other subjects, once the infusion of ANF was stopped, there was no longer a significant increase in urine flow ( Table 2) . Urine osmolality decreased with infusions of proANFs 1-30, 31-67, 79-98, and ANF, reflecting the diuresis they produced. The measured plasma osmolality did not change secondary to the infusion of these peptides, suggesting that the decreased urine osmolality observed was due to an increase in free water clearance. When free water clearance secondary to each of these atrial natriuretic peptides illustrated in Fig 4 was subjected to statistical evaluation, the increase in free water clearance did not reach a level of significance for any of the atrial natriuretic peptides. ProANFs 1-30, 31-67, and ANF each significantly (P<.05) increased sodium excretion, whereas proANF 79-98 did not significantly enhance sodium excretion ( Fig  5) . The control subjects who received 0.9% saline and those without a saline infusion did not have a significant increase in sodium excretion as observed in Table 3 . The enhanced sodium excretion of proANFs 1-30 and 31-67 varied from individual to individual as observed in Table  3 , but in each of these individuals, sodium excretion was prolonged in duration compared with ANF. Sodium excretion secondary to ANF had returned to baseline Peptide   0  30  60  80  100  120  150  180  210  240  270  300  ProANF 1-30  1  75  55  55  25  45  50  110  160  150  180  250  175  2  200  40  25  25  25  50  150  200  180  180  300  240  3  50  7  5  6  2  8  9  13  8  20  20  23  4  50  20  8  5  11  16  19  11  14  21  10  12  5  80  14  13  10  9  16  8  15 150  3  150  25  15  25  25  25  50  29  36  50  28  45  4  83  50  42  50  50  40  37  110  57  72  125  45  5  290  74  70  60  63  75  85  89  131  125  165  168  6  125  38  38  10  10  10  10  27  30  76  43  29   Mean±SEM 141 ±31 36±10 37+8 36±8 38±8 40±9 52±12 58±16 67±18 80±15 83±24 77±26   ANF  1  50  14  14  14  37  75  125  75  30  25  30  30  2  75  40  25  125  26  26  26  26  26  0  0  0  3  40  30  30  14  25  60  135  90  140  180  205  200  4  30  30  12  44  70  90  58  50  35  35  40  30  5  20  25  15  12  12  23  23  30  17  17  20  18  6  95  25  25  15  32  80   24  14  16  15  13  19 Mean±SEM 51 ±12 27±3 20±3 37±18 34±8 59±12 65±21 48+12 44±19 45±27 51±31 50±30 Control   1  15  15  20  10  8  10  10  10  20  10  15  10   2  16  19  30  16  25  16  24  28  30  22  17  18   3  50  13  13  7   9  9  10  12  12  13  9  12  4  13  16  15  9  7  9  12  15  14  14  14  9  5  13  5  13  5  8  8  10  13  13  13  11  10  6  30  9  13  8  8  8  13  12  12  10  9  10  Mean+SEM  22±6  12±2  17±2   9±2  11±3 10±1 13+2 15±3 17±3 14±2 13±1   12±1  Saline controls   1  15  5  8  7  5  3  6  6  7  6  8  3  2  200  187  62  30  30  32  52  77  64  65  80  60  3  100  16  15  8  10  15  20  16  25  15  26  30   4   82  43  125  77  75  41  40  46  51  63  28  33  5  32  17  14  9  9  7  16  16  12  18  16  14  6  105  50  38  20  24  27  34  36  30  30  29  24 Mean±SEM 89±26 53±27 44±18 25±11 26+11 21-+6 28±7 33±11 32±9 33±10 31±+10 27±8
Results
ProANF indicates atrial natriuretic factor prohormone; ANF, atrial natriuretic factor. Values are in milliliters. The first group of control subjects did not receive any saline, whereas the second group of control subjects received 20 mL of 0.9% saline (vehide) infused during a 60-minute time period. The zero-time urine reflects the amount in the bladder after overnight fasing. This value varied markedly from individual to individual, in part due to the fact that some individuals voided at home befbre arng for the study. A 1-hour baseline period was thus used to ensure that each subject was at their baseline. The 60-minute time period is each individual's own control time period for comparison of any increase in urine volume. The enhancement of urine volume by the respective peptides was significant at P<.01 when evaluated by one-way ANOVA. (Table 3) .
ProANF 79-98, although without natriuretic effects, was a significant (P<.05) stimulator of potassium excretion at its peak excretion compared with control ( Fig 6) . Only 1 of 6 subjects increased potassium excretion secondary to proANF 31-67 ( Table 4 ). Four of 6 subjects increased potassium excretion secondary to proANF 1-30 (Table 4 ), but this was not significant for the group (Fig 6) . Une plot: Evidence that atrial natriuretic factor prohormone (proANF) 1-30 exists as a separate entity in human plasma when plasma is subjected to high-performance gel permeation chromatography followed by proANF 1-30 radioimmunoassay.
In evaluation of hyman plasma, a sharp peak consistent with proANF 1-98 was observed at 9800 MW together with a large shoulder in fractions 69-72. The pure human synthetic form of proANF 1-30 peaks in fractions 69-70 as observed in Fig 7. Elution profiles of molecular weight markers (same as in Fig 7) are denoted by arrows on the top of graph. Vt indicates total volume of column; Vo, void volume of column.
Cumulative potassium excretion was greater with proANF 79-98 than with any other peptide. The circulating concentration of ANF did not increase with the infusion of proANFs 1-30, 31-67, or 79-98. The enhancement of urinary sodium and water excretion by NH2-terminal peptides was thus not due to their possible enhancement of ANF release but rather due to direct effects of the NH2-terminal peptides themselves. Likewise, infusion of any one of the N-terminal ANF prohormone peptides did not increase the Peptlde  0  30  60  80  100  120  150  180  210  240  270  300  ProANF 1-30  1  303  278  380  380  415  414  352  340  360  342  256  2  93  93  130  155  215  455  607  144  90  130  104  3  21  13  21  30  34  34  43  86  95  70  87   4  34  34  31  64  82  92  53  63  68  33  44  5  39  41  47  39  54  51  51  52  98  141  137  6  203  170  396  269  444  342  390  332  273  265 1  83  83  155  157  157  157  56  114  114  83  83  2  54  147  209  273  219  287  248  255  205  175  190  3  158  133  286  219  169  212  89  150  187  109  201  4  193  182  290  105  85  85  110  101  115  162  143  5  254  196  228  233  188  190  154  240  163  253  263  6  98  98  9  9  9  9  81  90  225  132  88   Mean±SEM   140+31 140±18 196±43 166+33 138±31 157±40 123±28 158±29 168±49 152+24 161±29   ANF  1  120  125  180  191  191  125  108  100  105  126  111  2  84  69  793  136  136  136  136  68  0  0  0  3  140  131  432  156  201  220  145  210  246  267  226  4  110  110  255  431  327  236  182  110  110  149  98  5  200  99  49  49  81  81  246  127  127  126  98  6  121  95  86  74  56  76  76  59  48  33  48   Mean±SEM  129±16 105±9 299±113 172±56 165±40 146±28 149±24 112±22 106±34 117±38 97+31  Control  1  20  45  29  22  32  34  26  29  27  59  39  2  112  200  170  268  174  178  215  224  161  118  97  3  41  50  39  58  59  41  53  60  56  34  35   4  41  41  55  40  45  46  65  68  69  62  32  5  17  59  36  33  52  48  62  55  41  37  41  6  32  42  52  60  58  59  47  59  56  47  55  Mean±SEM  44±14 73±26 64±21 80±38 70±21 68±22 78+28 82+29 68±19 60±13 50±10  Saline controls  1  16  23  32  34  26  36  35  35  31  39  15   2  523  386  293  293  312  250  267  281  171  195  80   3  92  110  71  76  112  99  75  121  112  152  100   4  304  238  173  165  150  193  204  136  141  113  128   5   101  65  67  69  55  82  70  51  88  72  63   6  368  304  245  290  328  294  314  262  250  248  198   Mean±SEM  234±80 188±59 147+44 155+47 164±52 159±42 161±47 148±42 132±31 137±32 97±25 ProANF indicates atrial natriuretic factor prohormone; ANF, atrial natriuretic factor. Values are uEq of Na+ excreted per minute. There is no "zero" time value because this time period was after an overnight fast; some subjects had to void at home before arriving for the study, making this "zero" different for each individual. The true basline for comparison of sodium excretion is the 60-minute time period (ie, immediately before the respective infusions). The first group of controls did not receive any saline, whereas the second group of controls received 20 mL of 0.9% saline (vehicle) infused during a 60-minute time period. The enhancement of sodium by ProANFs 1-30, 31-67, and ANF was significant at P<.01 when evaluated by one-way ANOVA. concentration of any of the other N-terminal ANF prohormone peptides in the circulation. Infusion of each atrial natriuretic peptide only increased its own respective concentration in the circulation. Thus, none of the four atrial natriuretic peptides enhance the activity of any of the other atrial natriuretic peptides as part of their mechanism of action. The circulating forms of each of the atrial natriuretic peptides in healthy humans recognized by the proANFs 1-30, 31-67, 79-98, and ANF RIAs were determined by HP-GPC (Figs 7 through 11). Human synthetic proANF 1-30 was found in 0.3-mL fractions 70-74, with fraction 71 having the predominant peak when evaluated by HP-GPC (Fig 7) . The human synthetic form of proANF 31-67 was found in 0.3-mL fractions 67-73, with the major peak in fraction 69 (Fig 7) . The human synthetic form of ANF was in 0.3-mL fractions 74-79, with the peak in fraction 75 ( Fig   7) . The elution profiles of I1'-proANF 1-30, I1'-proANF 31-67, and`PI-ANF were nearly identical to the unlabeled peptides, with their peak concentrations being in fractions 71, 70, and 76, respectively. Determination of the molecular forms in human plasma recognized by the proANF 1-30 RIA after similar HP-GPC analysis revealed that this assay recognized (1) a 9800-MW peptide consistent with the 98-amino acid N-terminus of the prohormone without the C-terminus (that is, ANF) attached to it and (2) a peak where the human synthetic form of proANF 1-30 eluates (Fig 8) . This suggests that proANF 1-30 exists in plasma as a separate entity from proANF 1-98 (Fig 8) . Under the respective peaks in Fig 8, one can observe that approximately 50% of what the proANF 1-30 assay immunologically recognizes is proANF 1-98, whereas 50% of what the assay recognizes in the circulation is proANF 1-30. Similar HP-GPC evaluation of plasma followed by proANF 31-67 RIA of 0.3-mL collected fractions revealed only one peak where the human sequence of proANF 31-67 eluates (Fig  9) . Neither proANlF 1-98 nor the ANF prohormone (that is, proANF 1-126) were immunologically recognized in plasma by the proANF 31-67 assay. Evaluation of human plasma by HP-GPC followed by ANF RIA also revealed only one peak-which eluated identically with the pure synthetic form of ANF (Fig 10) . ProANF 79-98 also exists as a distinct peptide in human plasma as determined by HP-GPC evaluation followed by proANF 79-98 RIA (Fig  11) . Human synthetic proANF 79-98 eluated in 0.3-mL fractions 76-81, with the peak in fraction 78. I1'-proANF 79-98 was similar with its peak in fraction 79. ProANF 79-98 eluted from plasma, where the pure synthetic human form of proANF 79-98 elutes, but, in addition, an elongated form of proANF 79-98 consistent with proANF 68-98 eluted as a second peak (Fig 11) . The proANF 79-98 RIA also immulogically recognizes proANF 1-98 ( Fig 11) . Examination of the area under the respective peaks in Fig 11 reveals that 25% of what the proANF 79-98 assay immulogically recognizes in the circulation is proANF 1-98, whereas 75% of what this assay recognizes is a combination of proANFs 68-98 and 79-98.
Discussion
ProANFs 1-30, 31-67, and 79-98 from the N-terminus of the 126-amino acid ANF prohormone as well as ANF (28-amino acid carboxy terminus of the prohormone) each significantly decreased systolic and diastolic blood pressures in healthy human subjects. Of the four atrial natriuretic peptides, proANF 31-67 and ANF lowered blood pressure to the greatest degree in healthy humans. The blood pressure-lowering properties of these atrial natriuretic peptides may be of physiological significance as well as possible pharmacological significance because proANFs 1-30, 31-67, and ANF circulate in healthy humans. [10] [11] [12] [13] [14] [15] [16] In the present investigation, the HP-GPC evaluation of human plasma confirms that proANFs 31-67 and 1-30 exist as distinct peptides in plasma along with proANF 1-98 and ANF. In addition, in the present investigation, it was demonstrated that proANF 79-98 exists as a distinct peptide in plasma. 
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ProANF indicates atrial natriuretic factor prohormone; ANF, atrial natriuretic factor.
Values are gEq/K+ excreted per minute. There is no "zero" time value because some subjects voided at home, making the "zero" different for each individual. The true baseline for comparison of potassium excretion is the 60-minute time point (ie, immediately before the respective infusions). The first group of controls did not receive any saline, whereas the second group of controls received 20 mL of 0.9% saline (vehicle) infused during a 60-minute time period. The enhancement of potassium excretion by proANF 79-98 (except subject 5), subjects 3 through 5 of proANF 1-30 and subject 5 of proANF 31-67, was significant at P<.01 when evaluated by the one-way ANOVA.
Thus, each of the peptides infused in the investigation circulate in the plasma of healthy humans. ProANF 68-98 also circulates. This peptide is formed when proteases cleave (1) between amino acids 67 and 68 to construct the C-terminal end of proANF 31-67 and (2) between amino acids 98 and 99 to form ANF. The peptide created from the production of ANF and proANF 31-67 is proANF 68-98. Further proteolytic processing between amino acids 78 and 79 of proANF 68-98 is then necessary to form proANF 79-98. Because proANF 68-98 is comprised of the same amino acids as proANF 79-98 (plus an 11 amino acid N-terminal extension), it is possible that proANF 68-98 may have similar properties as proANF 79-98. One would expect, however, that the 11-amino acid extension at the N-terminal end of proANF 79-98 may modify (enhance or decrease) the biological effects of proANF 79-98. A commercial source of proANF 68-98 is not currently available, however, to examine this hypothesis.
The present investigation compared the relative potency of the natriuretic and diuretic properties of the N-terminal ANF prohormone peptides versus ANF at the same 100 ng/kg body wt dose in humans. ProANFs 1-30 and 31-67 demonstrated equally potent diuretic and natriuretic properties to that of ANF; however, these natriuretic and diuretic properties persist significantly (P<.01) longer than those of ANF. The ability of the N-terminal ANF prohormone peptides to stimulate a more sustained diuresis and natriuresis is what one would expect, since their half-lives in the circulation are at least 15-fold longer than ANF. 20 The present investigation demonstrates that in humans, the mechanism of action for the N-terminal ANF prohormone peptides does not involve increasing ANF to produce effects. Rather, the effects of these peptides are correlated directly with their increased concentrations in the circulation. Because of their 10-fold higher plasma con-centrations10-15 and prolonged half-lives in comparison to ANF, it may well be that proANFs 1-30 and 31-67 contribute more to maintaining the natriuresis and diuresis that is observed secondary to normal physiological stimuli than does ANF.22 It is important to remember in this regard that ANF actually comprises only 2% of the circulating concentration of atrial natriuretic peptides within the circulation. 15 In addition to the much higher concentrations of proANF 1-30 and 31-67 in the circulation compared with ANF, the findings of the present investigation that they increase sodium excretion significantly longer than ANF suggest that the body has a very refined mechanism of maintaining sodium homeostasis: with the simultaneous release of proANFs 1-30, 31-67, and ANF in response to volume changes,17 acute enhancement of sodium excretion would appear due to the combined effects of each of these atrial natriuretic peptides while maintaining the enhancement of sodium excretion secondary to a volume load being exclusively secondary to proANFs 1-30 and 31-67. ProANF 79-98, without significant natriuretic properties in humans or animals,5 would not appear to be physiologically important for maintaining sodium metabolism, but this peptide does have diuretic properties. The exact mechanism(s) accounting for the differences in enhancement of sodium and/or potassium excretion secondary to the various peptides found in the present investigation are un-known. At the cellular level it is known, however, that these peptides do have different mechanisms of action, with proANF 31-67 having the ability to inhibit the Na+ /K+ ATPase in the inner medullary collecting duct, whereas ANF does not inhibit Na+/K+ ATPase.9 Further investigation will be necessary to determine the exact mechanism at the cellular level of differences in ability of the respective atrial natriuretic peptides to enhance sodium and/or potassium excretion that was demonstrated in the present investigation.
The natriuretic properties of proANFs 1-30 and 31-67 are especially impressive in light of the fact that (1) ANF has been reported to be a more potent natriuretic and diuretic agent than furosemide in direct comparative studies23 and (2) that proANFs 1-30 and 31-67 circulate normally at 11-to 17-fold higher concentrations than ANF.10-15 The 11to 17-fold higher circulating concentrations of proANFs 31-67 and 1-30 compared with ANF are found both during basal conditions and with release secondary to physiological stimuli such as head-out water immersion, where the atrium is stretched, releasing these peptides.17 These same 11to 17-fold higher circulating concentrations of proANFs 1-30 and 31-67 compared with ANF are observed during the volume expansion of a normal pregnancy24 or with the increased stimuli to release of these peptides with congestive heart failure.15 Thus, higher circulating concentrations of proANFs 1-30 and 31-67 compared with ANF are present under basal conditions, and this ratio of the NH2-terminal peptides to ANF remains constant with physiological and nonphysiological (ie, congestive heart failure) stimuli for release of these peptides.10"11 '15,17,18 Of the respective atrial natriuretic peptides, proANF 79-98 has the distinct property of being the strongest stimulator of potassium excretion in humans as well as in animals5 while at the same time possessing no natriuretic properties. This kaliuretic property suggests that proANF 79-98 may be important for the regulation of potassium metabolism in humans and animals. With respect to potassium metabolism, proANF 31-67 enhanced potassium excretion in only 1 of 6 human subjects and in none of the previous animal subjects. 5 Thus, proANF 31-67 may not be "potassium sparing" in all cases, as previous animal studies5 have suggested. In the majority of human individuals, proANF 31-67 does appear to be potassium sparing with its diuretic and natriuretic effects, but the present study indicates that in an occasional individual it is not, whereas within inbred strains of animals it is routinely potassium sparing.
